Monoclonal Antibody Products to Boost Drug Delivery Market
By HospiMedica International staff writers Posted on 11 Apr 2011 |
An array of new monoclonal antibody products will enter the market in coming years, driving growth in the global market for advanced drug delivery systems. These are the latest findings of Kalorama Information (New York, NY, USA), an independent market research firm.
Roche (Basel, Switzerland) is the clear leader in the market, and is involved in the marketing and distribution of five of the top monoclonal antibodies on the market - Avastin, Herceptin, Lucentis, Rituxan and Xolair, with at least four significant monoclonal products in development. Kalorama Information notes that competitors are actively trying to improve market share in the future and the market could look very different a few years from now. Abbott, Pfizer, and Novartis are all companies with monoclonal products in development. And although growth has slowed in recent years, these products are still leading expansion in biopharmaceuticals, representing a global market of US$60.6 billion.
"Monoclonal antibodies represent one of the largest classes of biotechnological drugs being developed. Several products are currently on the market and many more are expected within the next few years," said Bruce Carlson, publisher of Kalorama Information. "While you won't see the double digit growth that you saw in past years in this area, monoclonal antibodies remain an important part of this multibillion dollar market."
Monoclonals are antibodies designed to bind to a particular substance, such as a cancerous cell, which they can then detect and even treat. The first monoclonal antibody, Rituxan, was developed by Biogen IDEC (Weston, MA, USA), and received US Food and Drug Administration (FDA) approval in November 1997. The product is indicated for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphomas.
Related Links:
Kalorama Information
Roche
Biogen IDEC
Roche (Basel, Switzerland) is the clear leader in the market, and is involved in the marketing and distribution of five of the top monoclonal antibodies on the market - Avastin, Herceptin, Lucentis, Rituxan and Xolair, with at least four significant monoclonal products in development. Kalorama Information notes that competitors are actively trying to improve market share in the future and the market could look very different a few years from now. Abbott, Pfizer, and Novartis are all companies with monoclonal products in development. And although growth has slowed in recent years, these products are still leading expansion in biopharmaceuticals, representing a global market of US$60.6 billion.
"Monoclonal antibodies represent one of the largest classes of biotechnological drugs being developed. Several products are currently on the market and many more are expected within the next few years," said Bruce Carlson, publisher of Kalorama Information. "While you won't see the double digit growth that you saw in past years in this area, monoclonal antibodies remain an important part of this multibillion dollar market."
Monoclonals are antibodies designed to bind to a particular substance, such as a cancerous cell, which they can then detect and even treat. The first monoclonal antibody, Rituxan, was developed by Biogen IDEC (Weston, MA, USA), and received US Food and Drug Administration (FDA) approval in November 1997. The product is indicated for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphomas.
Related Links:
Kalorama Information
Roche
Biogen IDEC
Latest Business News
- Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
- Mindray to Acquire Chinese Medical Device Company APT Medical
- Olympus Acquires Korean GI Stent Maker Taewoong Medical
- Karl Storz Acquires British AI Specialist Innersight Labs
- Stryker to Acquire French Joint Replacement Company SERF SAS
- Medical Illumination Acquires Surgical Lighting Specialist Isolux
- 5G Remote-Controlled Robots to Enable Even Cross-Border Surgeries
- International Hospital Federation Announces 2023 IHF Award Winners
- Unprecedented AI Integration Transforming Surgery Landscape, Say Experts
- New WHO Guidelines to Revolutionize AI in Healthcare
- Getinge Acquires US-Based Medical Equipment Provider Healthmark Industries
- Global Surgical Lights Market Driven by Increasing Number of Procedures
- Global Capsule Endoscopy Market Driven by Demand for Accurate Diagnosis of Gastrointestinal Conditions
- Global OR Integration Market Driven by Need for Improved Workflow Efficiency and Productivity
- Global Endoscopy Devices Market Driven by Increasing Adoption of Endoscopes in Surgical Procedures
- Global Minimally Invasive Medical Devices Market Driven by Benefits of MIS Procedures